Holen Sie sich die Stockscreener-App
21.43
2.66%
-0.53
Handel nachbörslich:
21.43
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$21.96
Offen:
$21.58
24-Stunden-Volumen:
3.71M
Relative Volume:
0.32
Marktkapitalisierung:
$2.09B
Einnahmen:
$2.23B
Nettoeinkommen (Verlust:
$-248.39M
KGV:
-7.9665
EPS:
-2.69
Netto-Cashflow:
$-697.55M
1W Leistung:
-7.55%
1M Leistung:
+22.92%
6M Leistung:
-60.87%
1J Leistung:
-82.81%
1-Tages-Spanne:
$20.92
$21.82
1-Wochen-Bereich:
$20.92
$25.32
52-Wochen-Spanne:
$10.41
$138.81
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Firmenname
Sarepta Therapeutics Inc
Sektor
Branche
Telefon
617-274-4000
Adresse
215 FIRST STREET, CAMBRIDGE, MA
Vergleichen Sie SRPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
21.43 | 2.30B | 2.23B | -248.39M | -697.55M | -2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-22 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-07-29 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-07-29 | Bestätigt | H.C. Wainwright | Sell |
| 2025-07-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-07-29 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-07-28 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-07-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-07-24 | Eingeleitet | Citigroup | Sell |
| 2025-07-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-07-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-07-21 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-07-21 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | Herabstufung | Mizuho | Outperform → Neutral |
| 2025-07-21 | Herabstufung | Needham | Hold → Underperform |
| 2025-07-21 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-18 | Herabstufung | Needham | Buy → Hold |
| 2025-06-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-06-17 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-06-16 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-16 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | Herabstufung | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2025-04-02 | Hochstufung | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-11-27 | Bestätigt | Needham | Buy |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Sell |
| 2024-11-07 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-07-29 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-12-13 | Fortgesetzt | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-21 | Eingeleitet | Wedbush | Outperform |
| 2023-10-31 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-04 | Eingeleitet | Citigroup | Buy |
| 2023-03-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Bestätigt | BTIG Research | Buy |
| 2022-12-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Bestätigt | Needham | Buy |
| 2021-12-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-08-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-01-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-11 | Herabstufung | UBS | Buy → Neutral |
| 2021-01-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Eingeleitet | Mizuho | Buy |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-08-21 | Bestätigt | Needham | Buy |
| 2019-07-09 | Bestätigt | Morgan Stanley | Overweight |
| 2019-07-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-10-12 | Eingeleitet | Bernstein | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Bestätigt | RBC Capital Mkts | Outperform |
| 2018-09-14 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-09-06 | Eingeleitet | Credit Suisse | Outperform |
| 2018-08-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Bestätigt | Robert W. Baird | Outperform |
| 2018-06-20 | Bestätigt | Needham | Buy |
| 2018-06-19 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
Is Sarepta Therapeutics Inc. stock supported by strong cash flowsJuly 2025 Momentum & Short-Term High Return Strategies - newser.com
(SRPT) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Is Sarepta Therapeutics Inc. stock a good choice for value investorsNew Guidance & Safe Entry Trade Reports - newser.com
(SRPT) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Discipline and Rules-Based Execution in SRPT Response - news.stocktradersdaily.com
Precision Trading with Sarepta Therapeutics Inc. (SRPT) Risk Zones - news.stocktradersdaily.com
How Sarepta Therapeutics Inc. stock benefits from strong dollar2025 Big Picture & Safe Capital Growth Trade Ideas - newser.com
Why (SRPT) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
(SRPT) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Will Sarepta Therapeutics Inc. (AB3A) stock boost dividends furtherJuly 2025 Closing Moves & Weekly Market Pulse Alerts - newser.com
Trading Systems Reacting to (SRPT) Volatility - news.stocktradersdaily.com
Price-Driven Insight from (SRPT) for Rule-Based Strategy - news.stocktradersdaily.com
How Sarepta Therapeutics Inc. (SRPT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Sarepta Therapeutics: A Discounted Valuation Meets Breakthrough Pipeline - Seeking Alpha
Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal - MSN
Will Sarepta Therapeutics Inc. stock see insider buyingShare Buyback & Accurate Entry and Exit Point Alerts - newser.com
Sarepta Crisis Reveals Valuable Leadership Tips for Executives - Bloomberg Law News
November 28th Options Now Available For Sarepta Therapeutics (SRPT) - Nasdaq
How sentiment analysis helps forecast Sarepta Therapeutics Inc.July 2025 EndofMonth & Risk Controlled Stock Alerts - newser.com
Responsive Playbooks and the SRPT Inflection - news.stocktradersdaily.com
Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma Drive Innovation and Commercial Expansion - Yahoo Finance
Visualizing Sarepta Therapeutics Inc. stock with heatmapsCEO Change & High Return Trade Opportunity Guides - newser.com
Jefferies reiterates Buy rating on Sarepta stock, maintains $35 price target - Investing.com India
What's Going On Sarepta Stock On Wednesday?Sarepta Therapeutics (NASDAQ:SRPT) - Benzinga
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up After Analyst Upgrade - MarketBeat
Sarepta (SRPT) Faces Medicaid Coverage Pause for Duchenne Treatm - GuruFocus
Royal Bank Of Canada Boosts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $16.00 - MarketBeat
RBC Raises Price Target on Sarepta Therapeutics to $16 From $14, Keeps Sector Perform, Speculative Risk - MarketScreener
Why Sarepta Therapeutics Stock Is Rising Nearly 5% Premarket - MSN
Sarepta suffers a setback as N.Y. panel recommends state Medicaid pause coverage of Duchenne drug - statnews.com
AAV Gene Therapy Market Size to Skyrocket at 40.1% CAGR by 2034 - GlobeNewswire Inc.
Avoiding Lag: Real-Time Signals in (SRPT) Movement - news.stocktradersdaily.com
The Technical Signals Behind (SRPT) That Institutions Follow - news.stocktradersdaily.com
Sarepta Therapeutics Shares Up Pre-Bell Ahead of Presentation of Data on Muscle Dystrophy Studies - MarketScreener
A Look at Sarepta Therapeutics (SRPT) Valuation Following Recent Share Price Gains - Yahoo Finance
25,360 Shares in Sarepta Therapeutics, Inc. $SRPT Bought by 111 Capital - MarketBeat
Sarepta Therapeutics (SRPT) Is Up 23.3% After FDA Lifts Elevidys Hold and Advances SRP-1003 Trial – Has The Bull Case Changed? - Sahm
Sarepta Therapeutics (SRPT) Valuation in Focus After FDA Clears Elevidys and Company Restructures - Sahm
(SRPT) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Sarepta (SRPT) on Soars 15.7% on 5th Day Ahead of Clinical Trial Results - Yahoo Finance
(SRPT) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Sarepta: Q3 Earnings An Upcoming Catalyst, But Risks Undermine Any Contrarian Play (SRPT) - Seeking Alpha
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress - Placera.se
Sarepta Therapeutics Stock Skyrockets After FDA U-Turn – Gene Therapy Drama Explained! - ts2.tech
Sarepta Therapeutics (SRPT) Receives Sell Rating Amid Declining Growth - GuruFocus
Trading the Move, Not the Narrative: (SRPT) Edition - news.stocktradersdaily.com
Using RSI to spot recovery in Sarepta Therapeutics Inc.Weekly Trend Summary & AI Forecasted Stock Moves - newser.com
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Why Sarepta Therapeutics Inc. (AB3A) stock could rally stronglyProduct Launch & Accurate Buy Signal Alerts - newser.com
Liquidity Mapping Around (SRPT) Price Events - news.stocktradersdaily.com
Sarepta Therapeutics (NASDAQ:SRPT) Trading Up 10.4%What's Next? - MarketBeat
Finanzdaten der Sarepta Therapeutics Inc-Aktie (SRPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):